Our blog

The FDA has approved the use of sublingual apomorphine (KYNMOBI) in motor blocks, in Parkinson’s…

Compartir:

An intranasal levodopa has been authorized in the US to treat off blockages, called Inbrija….

Compartir:

Levodopa infusion pump We evaluate an ultraconcentrated levodopa administered subcutaneously in patients with motor fluctuations….

Compartir:

Our Unit has achieved to be activated in this outstanding project  and so serious pathology….

Compartir:

We appreciate the great effort made by our patients to contribute to the development of…

Compartir:

We have been activated in this trial that evaluates the safety of an innovative compound…

Compartir:

We have reached the first position, in December 2019, in the international inclusion of patients…

Compartir:

Grifols has reported to the press the positive result of the AMBAR trial in patients…

Compartir:

The UDIC has been selected to initiate a line of several clinical trials with this…

Compartir:

Our team will begin the evaluation of a novel drug that is administered intrathecally. It…

Compartir:

The UDIC will start a new clinical trial that evaluates the subcutaneous administration of levodopa,…

Compartir:

  On October 22, 2019, Biogen announced the positive result of its EMERGE clinical trial…

Compartir:
Page 1 of 31 2 3

1 Nuevo anticuerpo monoclonal antialfasinucleina Ensayo Clínico de fase II para evaluar eficacia y seguridad
en enfermedad de Parkinson inicial en pacientes que no reciben medicamentos antiparkinsonianos en el momento actual.
2 Nuevo fármaco antipsicótico en cualquier tipo de demencia. Ensayo de Fase III que evalúa un antipsicótico
en cualquier tipo de delirio o alucinaciones. Sin acción antidopaminérgica, especialmente indicado en Parkinson
o en situaciones de mala respuesta a los neurolepticos
Compartir: